LOGIN  |  REGISTER

Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO

May 13, 2025 | Last Trade: US$84.83 0.06 -0.07

SAN DIEGO / May 13, 2025 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022.

With more than 21 years of leadership experience at Dexcom, Mr. Leach helped steer the company’s biosensing platforms since the launch of its first commercial system. In his chief operating officer role, he provides end-to-end responsibility for product development at Dexcom as well as oversight of executive leadership functions, including global operations, research and development, quality management, regulatory and medical affairs. In his role as president, Mr. Leach will take on the additional responsibility of oversight of Dexcom’s corporate development and strategy efforts.

“My confidence in Dexcom’s future opportunities and the quality of our leadership have never been greater,” said Kevin Sayer, chairman and chief executive officer. “Jake has strengthened the company’s ability to innovate and achieve ambitious goals that will benefit the future of metabolic health. I have no doubt that he will build upon these accomplishments with his promotion to president.”

“There are few companies in the world with an opportunity to address the greatest challenges in global health while simultaneously benefiting our customers, shareholders and communities,” said Mr. Leach. “Taking on the role of president at this moment in our company’s history is incredibly exciting and I look forward to working with Kevin to lead Dexcom into a bright future.”

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

photo

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page